Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




3D Genome Mapping Tool to Improve Diagnosis and Treatment of Genetic Diseases

By LabMedica International staff writers
Posted on 11 Nov 2025

Standard laboratory tests often fail to detect complex DNA rearrangements that underlie many genetic diseases. More...

To bridge this diagnostic gap, researchers have developed a 3D chromosome mapping method that can uncover previously hidden structural variants with remarkable precision.

This breakthrough approach, developed by researchers from the University of Washington School of Medicine (Seattle, WA, USA), could redefine the diagnosis and management of genetic disorders. Unlike traditional one-dimensional DNA sequencing, which reads genetic code linearly, the new technique captures the three-dimensional structure of chromosomes inside the nucleus. This spatial mapping, known as genomic proximity mapping (GPM), is based on Hi-C sequencing and reveals how different regions of DNA physically interact. These interactions can expose deletions, duplications, and rearrangements that remain invisible to conventional sequencing technologies.

In the study published in The Journal of Molecular Diagnostics (Elsevier), the researchers applied GPM to DNA samples from 123 patients with suspected genetic conditions. The method accurately identified all known large chromosomal variants (110 deletions or duplications and 27 rearrangements) with 100% concordance compared to standard tests. Additionally, GPM uncovered 12 novel structural variants that conventional methods had missed, including cryptic rearrangements and complex multi-chromosomal events.

The technology also detected low-level mosaicism, where different cells in a patient carry different genetic changes—an important capability for accurate diagnosis and prognosis. Moreover, GPM requires less DNA than other advanced techniques such as optical genome mapping (OGM) or long-read sequencing (LRS), making it more practical for use on preserved or low-quality tissue samples.

“GPM offers broad clinical benefits. It enables high-resolution, comprehensive genomic characterization, even from compromised samples such as low-quality or archived preserved tissue,” said co-lead investigator Yajuan J. Liu, PhD. “As genomic medicine moves toward precision diagnostics, this new tool addresses current limitations in genetic testing, improving diagnostics and empowering doctors to provide personalized treatment, tailored monitoring, better prognosis, and improved family counseling.”

Related Links:
University of Washington School of Medicine


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.